On the other hand, AML+CYT significantly decreased the percentage of tubules with more than 15 ACROSIN-positive cells in the first week compared to CYT but was similar to CYT 2 and 2.5 weeks post treatment (Figure 5C). The gene discussed is ACR; the disease is acute myeloid leukemia.